After Reaching Milestone, Is Alkermes Plc – Ordinary Shares (NASDAQ:ALKS)’s Short Interest Revealing Something?

April 17, 2018 - By Adrian Erickson

Investors sentiment decreased to 0.75 in Q4 2017. Its down 0.29, from 1.04 in 2017Q3. It turned negative, as 42 investors sold Alkermes plc shares while 75 reduced holdings. 38 funds opened positions while 50 raised stakes. 152.34 million shares or 5.29% more from 144.69 million shares in 2017Q3 were reported.
Price T Rowe Assocs Md accumulated 16.46M shares or 0.15% of the stock. Sei Communication invested in 0.05% or 240,587 shares. Comml Bank Of Mellon Corporation has invested 0.02% in Alkermes plc (NASDAQ:ALKS). Apg Asset Nv stated it has 64,637 shares. Bnp Paribas Asset Mngmt Sa stated it has 642,104 shares. Commonwealth Natl Bank Of Australia has invested 0% in Alkermes plc (NASDAQ:ALKS). Principal Finance Group Inc invested in 45,439 shares or 0% of the stock. Wellington Mngmt Limited Liability Partnership holds 21.43 million shares or 0.26% of its portfolio. Robeco Institutional Asset Mngmt Bv holds 4,792 shares or 0% of its portfolio. Auxier Asset Mngmt reported 0.28% of its portfolio in Alkermes plc (NASDAQ:ALKS). 7,383 are held by Paloma Mngmt. Andra Ap reported 10,700 shares. Dimensional Fund Advisors Lp holds 0% of its portfolio in Alkermes plc (NASDAQ:ALKS) for 201,184 shares. Hall Laurie J Trustee stated it has 2,600 shares. Meeder Asset Mngmt invested in 0% or 324 shares.

The stock of Alkermes Plc – Ordinary Shares (NASDAQ:ALKS) registered a decrease of 2.49% in short interest. ALKS’s total short interest was 8.99 million shares in April as published by FINRA. Its down 2.49% from 9.22 million shares, reported previously. With 610,100 shares average volume, it will take short sellers 15 days to cover their ALKS’s short positions. The short interest to Alkermes Plc – Ordinary Shares’s float is 5.91%.

The stock increased 4.13% or $1.835 during the last trading session, reaching $46.265. About 1.39 million shares traded or 10.24% up from the average. Alkermes plc (NASDAQ:ALKS) has declined 0.51% since April 17, 2017 and is downtrending. It has underperformed by 12.06% the S&P500.

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The company has market cap of $7.17 billion. The companyÂ’s marketed products include ARISTADA for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It currently has negative earnings. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy.

Alkermes plc (NASDAQ:ALKS) Ratings Coverage

Among 9 analysts covering Alkermes (NASDAQ:ALKS), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Alkermes had 12 analyst reports since October 20, 2017 according to SRatingsIntel. Cowen & Co maintained Alkermes plc (NASDAQ:ALKS) rating on Friday, October 27. Cowen & Co has “Buy” rating and $63.0 target. Credit Suisse maintained Alkermes plc (NASDAQ:ALKS) on Friday, October 27 with “Outperform” rating. The company was maintained on Monday, April 2 by Cantor Fitzgerald. On Friday, February 23 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The firm has “Buy” rating given on Tuesday, November 28 by Credit Suisse. The firm has “Buy” rating by Mizuho given on Friday, October 20. Cantor Fitzgerald maintained Alkermes plc (NASDAQ:ALKS) rating on Tuesday, February 20. Cantor Fitzgerald has “Hold” rating and $50.0 target. The stock of Alkermes plc (NASDAQ:ALKS) earned “Hold” rating by Jefferies on Thursday, February 22. Cantor Fitzgerald maintained it with “Hold” rating and $53.0 target in Thursday, October 26 report.

Alkermes plc (NASDAQ:ALKS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: